Identifying Patients

A path to asthma control for different
patient types

Explore how DUPIXENT may help control symptoms in different
types of patients

Up to 84% of Adult Asthma Patients Present With Type 2 Inflammation1,2

Your appropriate patients with Type 2 inflammation, which can be both systemic and local, may benefit from DUPIXENT today3-5

Allergic Asthma Patient With Elevated Eosinophils

She is fearful that an asthma
attack will prevent her from
seeing friends and family

EOS 155 cells/µL

IgE 380 IU/mL


  • 2 severe exacerbations in the past year
  • Compromised lung function: 70% FEV1 % predicted
  • Diagnosed with asthma as a child
  • Positive skin test to a perennial aeroallergen
  • Triple therapy: ICS/LABA + LTRA

test

Explore lung function data

Severe Asthma Patient With Mucus Hypersecretion,
Decreased Lung Function, and Elevated Eosinophils

Difficulty breathing makes him nervous that he may miss out on quality time
with his
young son

EOS 320 cells/µL

IgE 430 IU/mL

FeNO 40 ppb

 

  • 2 severe exacerbations in the past year
  • Compromised lung function: 65% FEV1 % predicted
  • Diagnosed with adult-onset asthma at age 28
  • Lack of asthma control
  • Triple therapy: High-dose ICS/LABA + LAMA
Explore lung function data

OCS-Dependent Asthma 
Patient

Biomarker testing not 
required for this patient type

The burden of sudden
weight gain has left her
feeling discouraged

  • 2 severe exacerbations in the past year
  • Compromised lung function: 58% FEV1 % predicted
  • Diagnosed with adult-onset asthma at age 23
  • Lack of asthma control
  • Multiple courses of OCS treatment over
    6 months, potentially leading to6:
    • Symptoms of anxiety and depression
    • Weight gain
    • Type 2 diabetes
    • Vision problems
  • Triple therapy: High-dose ICS/LABA + LTRA


Patient profiles are representative and are not actual DUPIXENT patients.

Examples of patients with an eosinophilic phenotype or with OCS-dependent asthma.

FEV1, forced expiratory volume in 1 second; ICS, inhaled corticosteroid; LABA, long-acting beta agonist; LAMA, long-acting muscarinic antagonist; LTRA, leukotriene receptor antagonist.

 

NO BIOMARKER TESTING REQUIRED
for DUPIXENT

for 99% of OCS-dependent asthma patients who are commercially insured4

SEE THE FULL STUDY DESIGNS
Efficacy Across
Multiple Endpoints
See how DUPIXENT fared in 3 clinical trials.
VIEW EFFICACY AND SAFETY